Âé¶ą´«Ă˝É«ÇéƬ

Journal News

From the journals: JLR

Lisa Learman Laurel Oldach
Feb. 9, 2021

How does gastric bypass affect microRNA production? How does adiponectin fight fatty plaques? How is ceramide concentration sensed in cilia? We offer summaries of recent papers from the Journal of Lipid Research addressing these questions.

Gastric bypass affects microRNA production

Over one-third of people in the United States are obese, putting them at increased risk for heart disease, stroke, diabetes and certain cancers. Bariatric surgeries, procedures performed on the stomach or intestines to induce weight loss, can help these individuals lose weight. The most commonly performed weight loss surgery, a gastric bypass, creates a small pouch from the stomach that connects directly to the small intestine. After the surgery, the usable portion of the stomach is very small, limiting the amount a person can eat. In addition, swallowed food bypasses most of the stomach and some of the small intestine, causing less food to be absorbed.

FTJ-JLR-Gastric-bypass-445x471.jpg
/NIH Flickr
During a gastric bypass surgery, the top portion of the stomach is made into a small
pouch and connected directly to the small intestine, a process that decreases nutrient
absorption and eventually leads to weight loss.

Even before they lose weight, patients' metabolic and cardiovascular systems function better after the surgery. at the University of Manchester and a team of British and Australian researchers have discovered how high-density lipoprotein, or HDL, the so-called "good cholesterol," might be involved in this phenomenon.

Lipoproteins are small particles that carry cholesterol, other lipids, proteins and nucleic acid cargo between cells. HDL is considered helpful because it transports cholesterol out of tissues and to the liver, where it can be neutralized. However, researchers do not yet understand exactly how HDL controls the removal of cholesterol from tissues. Recently, researchers have found that HDL particles can carry microRNAs, short RNAs that impede the expression of genes. In in the Journal of Lipid Research, Ho and colleagues demonstrate that the microRNAs within HDL particles may confer the protective effects of gastric bypass.

The group showed that HDL's cholesterol efflux capacity is improved after gastric bypass, independent of weight loss, and that this improved function correlates with the levels of certain microRNAs within the HDL particle. The discovery of microRNAs that regulate the removal of cholesterol from tissues gives researchers a potential therapeutic avenue in the treatment of obesity and metabolic disorders.

How adiponectin fights fatty plaques

The formation of fatty plaques in the arteries, called atherogenesis, can lead to problems such as heart attack, stroke or even death. Fat cells, called adipocytes, secrete a protein called adiponectin into the bloodstream, where it can block these fatty plaques from forming, but researchers do not yet know how adiponectin performs this protective function. In a in the Journal of Lipid Research, investigator from Shinshu University and a team of Japanese researchers describe how adiponectin protects against atherogenesis by blocking the uptake of specific types of low-density lipoprotein, or LDL, that have atherogenic properties.

These atherogenic varieties, such as oxidized LDL and electronegative LDL, enter cells via scavenger receptors and trigger a cell signaling cascade that causes plaque formation. The researchers found that the more adiponectin there was in the cell culture medium, the less efficiently LDL could gain entry into the cells. The decrease in plaque-causing LDL uptake led to lower levels of LDL-induced atherogenic signaling cascades. The authors used the same concentrations of adiponectin found in the human body, strongly supporting the idea that blocking atherogenic LDL uptake is a physiological function of the protein and not just something that occurs in artificial laboratory conditions. Overall, the results provide insights into how adiponectin protects us from developing fatty arteries and offer a new therapeutic target in the treatment of atherosclerosis-related diseases.

Ceramide anchors cilia proteins

Cellular cilia depend on an axle-and-spoke arrangement of microtubules for structural integrity, meaning that to generate cilia, a cell must synchronize microtubule and membrane extension. The plasma membrane lipid ceramide regulates the length of cilia and transport along growing cilia, but researchers have been uncertain of how ceramide concentration is sensed.

JLR-FTJ-Epithelial-cell-Cilia-445x371.jpg
Esaah6/Wikimedia Commons
A recent article in the Journal of Lipid Research gives new insight into how cilia
are built.

In a in the Journal of Lipid Research, and a team from the University of Kentucky report that lipid modification of cysteine residues on a microtubule protein allows direct binding to ceramide in the membrane. Microtubules are made up of two subunits, alpha tubulin and beta tubulin, each of which can be post-translationally modified. A subset of acetylated alpha tubulin is palmitoylated, and the researchers showed using immunoprecipitation and fluorescence microscopy that palmitoylation allows tubulin to bind to ceramide. It also helps tubulin recruit a GTPase involved in protein transport into the cilia.

The authors report that the interaction between ceramide and palmitoyl-tubulin is required for new cilia to form in human-derived neural progenitor cells, where they eventually mature into dendrites and axons. The interaction is also necessary for a distantly related eukaryotic algae to grow flagella.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Lisa Learman

Lisa Nicole Learman is a Ph.D. candidate studying molecular neuroscience at Johns Hopkins University School of Medicine. She is passionate about dystopian fiction, increasing public understanding of science and the music of Charles Mingus.

Laurel Oldach

Laurel Oldach is a former science writer for the ASBMB.

Related articles

From the Journals: JLR
Sephra Rampersad
From the journals: JLR
Swarnali Roy
From the journals: JBC
Ken Farabaugh
From the journals: JLR
Meric Ozturk
From the journals: JLR
Nivedita Uday Hegdekar

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

How scientists identified a new neuromuscular disease
Feature

How scientists identified a new neuromuscular disease

Aug. 14, 2025

NIH researchers discover Morimoto–Ryu–Malicdan syndrome, after finding shared symptoms and RFC4 gene variants in nine patients, offering hope for faster diagnosis and future treatments.

Unraveling cancer’s spaghetti proteins
Profile

Unraveling cancer’s spaghetti proteins

Aug. 13, 2025

MOSAIC scholar Katie Dunleavy investigates how Aurora kinase A shields oncogene c-MYC from degradation, using cutting-edge techniques to uncover new strategies targeting “undruggable” molecules.

How HCMV hijacks host cells — and beyond
Profile

How HCMV hijacks host cells — and beyond

Aug. 12, 2025

Ileana Cristea, an ASBMB Breakthroughs webinar speaker, presented her research on how viruses reprogram cell structure and metabolism to enhance infection and how these mechanisms might link viral infections to cancer and other diseases.

Understanding the lipid link to gene expression in the nucleus
Profile

Understanding the lipid link to gene expression in the nucleus

Aug. 11, 2025

Ray Blind, an ASBMB Breakthroughs speaker, presented his research on how lipids and sugars in the cell nucleus are involved in signaling and gene expression and how these pathways could be targeted to identify therapeutics for diseases like cancer.

Receptor antagonist reduces age-related bone loss in mice
Journal News

Receptor antagonist reduces age-related bone loss in mice

Aug. 6, 2025

Receptor antagonist reduces bone loss and promotes osteoblast activity in aging mice, highlighting its potential to treat osteoporosis. Read more about this recent JBC paper.

Engineered fusion protein targets kiwifruit pathogen
Journal News

Engineered fusion protein targets kiwifruit pathogen

Aug. 6, 2025

Synthetic protein selectively kills kiwifruit pathogen, offering a promising biocontrol strategy for agriculture. Read more about this recent JBC paper.